COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
Status:
Recruiting
Trial end date:
2020-06-14
Target enrollment:
Participant gender:
Summary
The most prevalent complication of COVID-19 infection is respiratory failure from severe
acute respiratory syndrome (SARS), the leading cause of mortality. There is increasing
indication that the decompensation in severe COVD-19 infection may be due to a cytokine storm
syndrome. This hyperinflammatory syndrome results in a fulminant and fatal hypercytokinemia
and multiorgan failure.
Approximately 15% of patients with COVID-19 infection are hospitalized and 20-30% of these
hospitalized patients require ICU care and/or mechanical ventilation. Overall mortality in
hospitalized patients is approximately 20-25%. There is significant interest in therapies
that can be given upstream to reduce the rate of mechanical ventilation and thus mortality.
We hypothesize that treatment with colchicine in COVID-19 moderate-severe patients may
decrease the risk of progression into ARDS requiring increased oxygen requirements,
mechanical ventilation, and mortality.